Methods of tumor vaccination
A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.
1. A method for generating an immune response against a solid tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a solid tumor site, wherein the first composition comprises a CD34-positive, CD1a-positive, and CD83-positive cell comprising CRM197 or a nucleic acid encoding CRM197; and
a tumor-marking step comprising administering a second composition to the subject at the solid tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197, thereby generating an immune response against the solid tumor in the subject.
2. The method of claim 1 , wherein the CD34-positive, CD1a-positive, and CD83-positive cell is differentiated from DCOne.
3. The method of claim 1 , wherein the tumor-marking step comprises administering the second composition into the tumor.
4. The method of claim 1 , wherein the vaccination step comprises administering the first composition into an organ system that is different to the organ system in which the tumor resides.
5. The method of claim 1 , wherein the vaccination step comprises administering the first composition into a site contralateral to the tumor.
6. The method of claim 1 , wherein the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
7. The method of claim 1 , wherein the second composition further comprises a tumor targeting component selected from the group consisting of a tumor-specific virus, an oncolytic virus, and a tumor-specific nanoparticle.
8. The method of claim 1 , wherein the solid tumor is glioblastoma or ovarian cancer.
9. The method of claim 1 , wherein the subject is selected from the group consisting of a human, a domesticated animal, and an animal suitable for veterinary healthcare.
10. A method for generating an immune response against a solid tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a solid tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197; and
a tumor-marking step comprising administering a second composition to the subject at the solid tumor site, wherein the second composition comprises a CD34-positive, CD1a-positive, and CD83-positive cell comprising CRM197 or a nucleic acid encoding CRM197,
thereby generating an immune response against the solid tumor in the subject.
11. The method of claim 10 , wherein the CD34-positive, CD1a-positive, and CD83-positive cell is differentiated from DCOne.
12. The method of claim 10 , wherein the tumor-marking step comprises administering the second composition into the tumor.
13. The method of claim 10 , wherein the vaccination step comprises administering the first composition into an organ system that is different to the organ system in which the tumor resides.
14. The method of claim 10 , wherein the vaccination step comprises administering the first composition into a site contralateral to the tumor.
15. The method of claim 10 , wherein the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
16. The method of claim 10 , wherein the second composition further comprises a tumor targeting component selected from the group consisting of a tumor-specific virus, an oncolytic virus, and a tumor-specific nanoparticle.
17. The method of claim 10 , wherein the solid tumor is glioblastoma or ovarian cancer.
18. The method of claim 10 , wherein the subject is selected from the group consisting of a human, a domesticated animal, and an animal suitable for veterinary healthcare.
19. A method for generating an immune response against a solid tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a solid tumor site, wherein the first composition comprises a first CD34-positive, CD1a-positive, and CD83-positive cell comprising CRM197 or a nucleic acid encoding CRM197; and
a tumor-marking step comprising administering a second composition to the subject at the solid tumor site, wherein the second composition comprises a second CD34-positive, CD1a-positive, and CD83-positive cell comprising CRM197 or a nucleic acid encoding CRM197,
thereby generating an immune response against the solid tumor in the subject.
20. The method of claim 19 , wherein the first and the second CD34-positive, CD1a-positive, and CD83-positive cell are differentiated from DCOne.